-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GT7jIlmYSWrwh1zQqZKjPf0JsuAWKR5Cr+CSMZ3Gz2UdrSjlkI4LQkka+jJnpmRj HQCKSVk/u/o2VlpwOoxI7A== 0001014156-04-000003.txt : 20040114 0001014156-04-000003.hdr.sgml : 20040114 20040114135601 ACCESSION NUMBER: 0001014156-04-000003 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20031231 FILED AS OF DATE: 20040114 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WATTLETON FAYE CENTRAL INDEX KEY: 0001014156 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 04524600 BUSINESS ADDRESS: STREET 1: 25 WEST 43RD STREET STREET 2: SUITE 1014 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 212 391 7718 MAIL ADDRESS: STREET 1: 767 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10153 4/A 1 edgar.xml PRIMARY DOCUMENT X0201 4/A2003-12-312004-01-05 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001014156 WATTLETON FAYE 300 CENTRAL PARK WEST APT. 15H NEW YORK NY 10024 1000Common stock, $.01 par value per share2003-12-314A05424.61A4404DOptions to purchase common stock, $.01 par value per share4.612003-12-314A050004.61A2004-12-312013-12-31Common stock, $01 par value pe r share500090000DThese shares were granted pursuant to the Company's Stock Compensation Plan for Outside Directors, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $2,500, until he is no longer an Outside Director. On December 31, 2003, the fair market value of the Common Stock, based on the closing price, was $4.61.These options will become fully vested and immediately exercis able on 12/31/2004.This stock grant was originally reported in Table 1 Columns 3 and 4 with the incorrect transaction codes. The stock grant was originally reported in Column 3 as "D" instead of "A" and in Column 4 as "D" for securities disposed of instead of "A" for securities acquired. /s/ Faye Wattleton2004-01-14 -----END PRIVACY-ENHANCED MESSAGE-----